COMPANY

Biofluidica, Inc.

HQ: Cary, NC source · biofluidica.com ↗ · Midwest

Service / Tools company

Keywords: liquid biopsy

Location: Cary, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

14NIH grants

NIH awards 14

Annual award amounts. Total $7.2M.

Aug 31, 2020 NIH award 5R44CA224848-03 FY2020: $556,708 awarded for that fiscal year; activity R44 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Increased sensitivity of minimal residual disease m source ↗
Sep 18, 2019 NIH award 4R44CA224848-02 FY2019: $837,994 awarded for that fiscal year; activity R44 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Increased sensitivity of minimal residual disease m source ↗
Apr 19, 2019 NIH award 1R43HD098942-01 FY2019: $291,545 awarded for that fiscal year; activity R43 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. A microfluidic platform for the high-throughput iso source ↗
Sep 18, 2018 NIH award 1R43CA228923-01A1 FY2018: $286,548 awarded for that fiscal year; activity R43 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Parallel and high throughput isolation of cfDNA t source ↗
Jul 18, 2018 NIH award 1R44CA224848-01A1 FY2018: $348,768 awarded for that fiscal year; activity R44 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Increased sensitivity of minimal residual disease source ↗
Jul 13, 2018 NIH award 1R43CA232848-01 FY2018: $239,138 awarded for that fiscal year; activity R43 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Parallel and high throughput isolation of cancer ce source ↗
Feb 21, 2018 NIH award 5R44CA213595-02 FY2018: $712,071 awarded for that fiscal year; activity R44 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Rapid detection of minimal residual disease in acut source ↗
Feb 23, 2017 NIH award 1R44CA213595-01 FY2017: $798,225 awarded for that fiscal year; activity R44 (SBIR); PI MULLER, ROLF; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Rapid detection of minimal residual disease in acut source ↗
Aug 30, 2016 NIH award 5R44CA203221-02 FY2016: $687,200 awarded for that fiscal year; activity R44 (SBIR); PI HUPERT, MATEUSZ LUKASZ; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Integrated Systems for the Analysis of Ci source ↗
Jul 28, 2016 NIH award 5R43EB021212-02 FY2016: $199,833 awarded for that fiscal year; activity R43 (SBIR); PI HUPERT, MATEUSZ LUKASZ; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. CTC Screening Assay to Address Health Dis source ↗
Sep 24, 2015 NIH award 1R44CA203221-01 FY2015: $808,983 awarded for that fiscal year; activity R44 (SBIR); PI HUPERT, MATEUSZ LUKASZ; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Integrated Systems for the Analysis of Ci source ↗
Sep 17, 2015 NIH award 1R43EB021212-01 FY2015: $199,848 awarded for that fiscal year; activity R43 (SBIR); PI HUPERT, MATEUSZ LUKASZ; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. CTC Screening Assay to Address Health Dis source ↗
2013 NIH contract (government contract; not a grant and not an investment round) 261201300071C-0-0-1 FY2013: $999,873 awarded for that fiscal year; activity N44 (OTHER_NIH); PI HUPERT, MATEUSZ LUKASZ; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Low-cost m source ↗
2010 NIH contract (government contract; not a grant and not an investment round) 261201000066C-0-0-1 FY2010: $199,517 awarded for that fiscal year; activity N43 (OTHER_NIH); PI HUPERT, MATEUSZ LUKASZ; recipient as written: BIOFLUIDICA, INC, Lawrence, KS. Low-Cost M source ↗